Tarbox Group Inc. raised its position in Gilead Sciences, Inc. (NASDAQ:GILD) by 0.0% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 6,488 shares of the biopharmaceutical company’s stock after buying an additional 1 shares during the period. Tarbox Group Inc.’s holdings in Gilead Sciences were worth $441,000 as of its most recent filing with the SEC.
Several other hedge funds have also bought and sold shares of the company. Norges Bank purchased a new stake in shares of Gilead Sciences during the fourth quarter valued at approximately $997,048,000. Renaissance Technologies LLC raised its stake in shares of Gilead Sciences by 170.9% in the fourth quarter. Renaissance Technologies LLC now owns 5,274,948 shares of the biopharmaceutical company’s stock valued at $377,739,000 after buying an additional 3,327,900 shares during the last quarter. State Street Corp raised its stake in shares of Gilead Sciences by 4.5% in the fourth quarter. State Street Corp now owns 60,448,831 shares of the biopharmaceutical company’s stock valued at $4,328,739,000 after buying an additional 2,587,072 shares during the last quarter. Asset Management One Co. Ltd. raised its stake in shares of Gilead Sciences by 516.2% in the fourth quarter. Asset Management One Co. Ltd. now owns 2,410,521 shares of the biopharmaceutical company’s stock valued at $172,719,000 after buying an additional 2,019,344 shares during the last quarter. Finally, Numeric Investors LLC raised its stake in shares of Gilead Sciences by 173.5% in the fourth quarter. Numeric Investors LLC now owns 2,820,505 shares of the biopharmaceutical company’s stock valued at $201,976,000 after buying an additional 1,789,101 shares during the last quarter. 73.99% of the stock is owned by institutional investors and hedge funds.
Gilead Sciences, Inc. (NASDAQ GILD) opened at 70.52 on Monday. Gilead Sciences, Inc. has a 1-year low of $63.76 and a 1-year high of $88.85. The company has a market cap of $92.15 billion, a PE ratio of 7.45 and a beta of 1.20. The stock’s 50 day moving average price is $65.46 and its 200-day moving average price is $69.00.
Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings results on Tuesday, May 2nd. The biopharmaceutical company reported $2.20 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $2.18 by $0.02. The firm had revenue of $6.51 billion for the quarter, compared to analyst estimates of $6.66 billion. Gilead Sciences had a net margin of 43.42% and a return on equity of 76.64%. On average, analysts forecast that Gilead Sciences, Inc. will post $8.35 earnings per share for the current year.
The company also recently declared a quarterly dividend, which will be paid on Thursday, June 29th. Stockholders of record on Friday, June 16th will be given a dividend of $0.52 per share. This represents a $2.08 annualized dividend and a dividend yield of 2.95%. The ex-dividend date of this dividend is Wednesday, June 14th. Gilead Sciences’s payout ratio is presently 21.99%.
Several analysts recently commented on the company. Deutsche Bank AG assumed coverage on Gilead Sciences in a report on Friday. They issued a “buy” rating and a $79.00 price objective for the company. Leerink Swann reaffirmed a “market perform” rating on shares of Gilead Sciences in a report on Thursday. BidaskClub raised Gilead Sciences from a “strong sell” rating to a “sell” rating in a report on Thursday. Vetr downgraded Gilead Sciences from a “strong-buy” rating to a “buy” rating and set a $75.40 target price on the stock. in a research report on Wednesday, June 21st. Finally, William Blair reiterated an “outperform” rating on shares of Gilead Sciences in a research report on Friday, June 16th. One equities research analyst has rated the stock with a sell rating, twelve have issued a hold rating, sixteen have given a buy rating and one has issued a strong buy rating to the stock. Gilead Sciences currently has an average rating of “Buy” and a consensus target price of $80.58.
In other news, EVP Gregg H. Alton sold 5,000 shares of Gilead Sciences stock in a transaction that occurred on Thursday, March 30th. The shares were sold at an average price of $67.48, for a total transaction of $337,400.00. Following the sale, the executive vice president now owns 117,988 shares of the company’s stock, valued at approximately $7,961,830.24. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director John Francis Cogan sold 9,943 shares of Gilead Sciences stock in a transaction that occurred on Tuesday, May 9th. The shares were sold at an average price of $67.25, for a total transaction of $668,666.75. Following the sale, the director now directly owns 47,562 shares in the company, valued at approximately $3,198,544.50. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 88,276 shares of company stock worth $5,932,578. Corporate insiders own 1.30% of the company’s stock.
Gilead Sciences Company Profile
Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.
Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD).
This story was originally published by sleekmoney (https://sleekmoney.com) and is the sole property of sleekmoney. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at https://sleekmoney.com/tarbox-group-inc-raises-position-in-gilead-sciences-inc-gild/1939437.html
Receive News & Ratings for Gilead Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.